Sanctuary Advisors LLC grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 103.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,649 shares of the company's stock after purchasing an additional 3,898 shares during the period. Sanctuary Advisors LLC's holdings in Neurocrine Biosciences were worth $961,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of NBIX. Fifth Third Bancorp grew its stake in shares of Neurocrine Biosciences by 14.7% in the second quarter. Fifth Third Bancorp now owns 716 shares of the company's stock valued at $99,000 after buying an additional 92 shares in the last quarter. Bank of New York Mellon Corp grew its position in Neurocrine Biosciences by 1.4% in the second quarter. Bank of New York Mellon Corp now owns 934,404 shares of the company's stock valued at $128,639,000 after acquiring an additional 13,069 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of Neurocrine Biosciences by 40.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 710,600 shares of the company's stock valued at $97,828,000 after purchasing an additional 203,934 shares during the period. Burney Co. lifted its position in shares of Neurocrine Biosciences by 4.1% during the second quarter. Burney Co. now owns 82,578 shares of the company's stock worth $11,369,000 after purchasing an additional 3,236 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Neurocrine Biosciences by 41.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 90,018 shares of the company's stock valued at $12,393,000 after purchasing an additional 26,195 shares during the period. Hedge funds and other institutional investors own 92.59% of the company's stock.
In other news, insider Ingrid Delaet sold 1,091 shares of the firm's stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total transaction of $147,285.00. Following the transaction, the insider now owns 2,507 shares in the company, valued at approximately $338,445. This trade represents a 30.32 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jude Onyia sold 2,331 shares of the company's stock in a transaction on Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the sale, the insider now owns 15,449 shares of the company's stock, valued at $1,951,054.21. This represents a 13.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.30% of the stock is owned by corporate insiders.
A number of brokerages have commented on NBIX. Raymond James reissued an "outperform" rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Wedbush restated an "outperform" rating and set a $148.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Barclays reduced their target price on Neurocrine Biosciences from $180.00 to $160.00 and set an "overweight" rating for the company in a research note on Monday, September 9th. Royal Bank of Canada lowered their price target on Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating for the company in a report on Friday, October 4th. Finally, HC Wainwright reissued a "buy" rating and issued a $190.00 price target on shares of Neurocrine Biosciences in a report on Monday, December 16th. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $166.00.
Read Our Latest Research Report on NBIX
Shares of NASDAQ:NBIX opened at $135.42 on Monday. The firm has a market cap of $13.71 billion, a price-to-earnings ratio of 36.31 and a beta of 0.34. Neurocrine Biosciences, Inc. has a 1 year low of $110.95 and a 1 year high of $157.98. The business has a fifty day simple moving average of $123.99 and a 200 day simple moving average of $130.57.
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Neurocrine Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.
While Neurocrine Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.